



EXTRAORDINARY GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES

The following item on the agenda of the extraordinary general meeting of argenx SE (the "**Company**") shall be discussed and/or put to a vote. The number in the list correspond to the number on the agenda.

2. Appointment of Ana Cespedes as non-executive director to the board of directors of the Company (voting item)

The Board proposes to appoint Ana Cespedes as a non-executive director of the Company with effect from the date of this extraordinary general meeting.

The proposed appointment is for a term ending on the day of the annual general meeting of shareholders to be held in 2026. The proposed appointment is in accordance with the Company's articles of association and takes into account the pursued composition and profile of the Board as apparent from the Company's profile for the non-executive directors which is available on the Company website.

In making this proposal, the Board has taken into consideration Ana Cespedes's skills, knowledge and expertise built up during her career.

Dr. Ana Céspedes (age 49) is Chief Operating Officer of IAVI, a global organization dedicated to developing accessible vaccines and antibodies for infectious diseases. Since September 2018, she oversees Finance & Administration, Legal & Compliance, Business Development, HR, Operational Excellence, Global Access, External Affairs, Communications, and Regional Operations. Over the past 22 years, Ana has held numerous positions of increasing responsibility in health consulting, biotechnology, pharma, and global health, within EMD Serono (Boston, USA), Merck KGaA (Darmstadt, Germany), Serono Iberia (Spain, Portugal), and Arthur Andersen. Among them, Céspedes was Global Head of Market Access and Pricing for Merck KGaA (Darmstadt, Germany) and Head of Corporate Affairs for Merck. S.L. (Spain), and for Serono Iberia. Ana is co-founder of the Think Tank Spanish Women Leaders in Life Sciences (SWL), Board Member (Healthcare Chapter) of the IESE Business School, Faculty member of EADA Business School, and member of the Scientific Advisory Board of the ProPatients Institute. She holds a PhD in Pharmacy, a Master's in General Management (PDG) from the IESE Business School and an Executive Certification in Strategy & Innovation from MIT.

Ana brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. She puts forward a breakthrough mindset and a strong passion to enable patient access.

It is envisaged that Ana will join the Remuneration and Nomination Committee and the Commercialization Committee of the Board of Directors.

Ana Cespedes holds no shares in argenx SE.